Pancreatic Cancer Therapy
New pancreatic cancer therapy study findings have been reported by scientists at National Cancer Center Hospital
Published in Drug Week, April 11th, 2008
Investigators publish new data in the report 'A late phase II study of S-1 for metastatic pancreatic cancer.' According to a study from Tokyo, Japan, "This study evaluated the antitumor effect and safety of S-1, an oral fluoropyrimidine derivative, in patients with metastatic pancreatic cancer. Chemo-naive patients with pancreatic adenocarcinoma, and measurable metastatic lesions were enrolled."
"S-1 was administered orally twice daily after meals at a dose of 80, 100, or 120 mg/day for body surface areas (BSAs) of less than 1.25 m2, between 1.25 m2 and less than 1.5, or 1.5 m2 or greater, respectively, for 28 consecutive days, followed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2008-04-11)
More Articles from Drug Week
- Breast Cancer
Hormone replacement therapy increases breast cancer recurrence - Cord Blood
Umbilical cord blood cell therapy in an animal model of Alzheimer's disease - Depression
PTSD associated with more, longer hospitalizations - Drug Development
Pain receptor in brain may be linked to learning and memory - Drug Safety
FDA deadlines may compromise drug safety by rushing approval - Hypertension
Relaxation training may improve control of hard-to-treat systolic hypertension - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
